1. Show article details.

    BRIEF-Savara Says Rob Neville Resigns As Chairman And Chief Executive Officer

    Reuters – 8:17 AM ET 09/11/2020

    Savara Inc (SVRA): * SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES. * Savara Inc (SVRA) - ROB NEVILLE RESIGNS AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER. * Savara Inc (SVRA) - HAS APPOINTED MATTHEW PAULS AS CHAIRMAN AND INTERIM CEO. * Savara Inc (SVRA) - TANELI JOUHIKAINEN, PRESIDENT AND CHIEF BUSINESS OFFICER, HAS ALSO RESIGNED TO PURSUE OTHER OPPORTUNITIES Source text for Eikon: Further company coverage:

  2. Show article details.

    Savara Announces Senior Management Changes

    Business Wire – 8:05 AM ET 09/11/2020

    Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer Savara Inc. (SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer and from the Board of Directors, effective immediately, to pursue other opportunities.

  3. Show article details.

    Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

    Business Wire – 4:05 PM ET 09/09/2020

    Savara Inc. (SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.

  4. Show article details.

    BRIEF-Savara Announces New England Journal Of Medicine (Nejm) Publication Of Impala Study Results

    Reuters – 8:16 AM ET 09/08/2020

    Savara Inc (SVRA): * SAVARA ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION OF IMPALA STUDY RESULTS Source text for Eikon: Further company coverage:

  5. Show article details.

    Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

    Business Wire – 8:05 AM ET 09/08/2020

    Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP Savara Inc. (SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM.

  6. Show article details.

    BRIEF-Savara To Discontinue Exploratory Encore Study Evaluating Molgradex For Treatment Of NTM Lung Infection

    Reuters – 4:16 PM ET 09/03/2020

    Savara Inc (SVRA): * SAVARA TO DISCONTINUE EXPLORATORY ENCORE STUDY EVALUATING MOLGRADEX FOR THE TREATMENT OF NTM LUNG INFECTION IN PEOPLE LIVING WITH CYSTIC FIBROSIS. * Savara Inc (SVRA) - ENCORE STUDY STOPPED ENROLLING IN MARCH 2020 DUE TO LIMITATIONS CAUSED BY COVID-19. * Savara Inc (SVRA) - DECISION TO DISCONTINUE ENCORE STUDY WAS NOT BASED ON SAFETY CONCERNS.

  7. Show article details.

    Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

    Business Wire – 4:05 PM ET 09/03/2020

    Savara Inc. (SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial lung infection in people living with cystic fibrosis.

  8. Show article details.

    BRIEF-Savara- Announces Final Clinical Study Design For Impala 2, Next Phase 3 Study Of Molgradex In Autoimmune Pulmonary Alveolar Proteinosis

    Reuters – 4:38 PM ET 08/06/2020

    Savara Inc (SVRA): * SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q2 LOSS PER SHARE $0.16. * Q2 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA. * SAVARA- ANNOUNCES FINAL CLINICAL STUDY DESIGN FOR IMPALA 2, NEXT PHASE 3 STUDY OF MOLGRADEX IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS.

  9. Show article details.

    Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

    Business Wire – 4:02 PM ET 08/06/2020

    Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis Study Expected to Start in Q1 2021 Savara Inc. (SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

  10. Show article details.

    Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

    Business Wire – 8:05 AM ET 08/05/2020

    Savara Inc. (SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

  11. Show article details.

    Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

    Business Wire – 8:05 AM ET 07/30/2020

    Savara Inc. (SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Shareholders and other interested parties may access the call by dialing 239-3120 from the U.S., 669-9657 from Canada, and 542-4127 from elsewhere outside the U.S. and requesting the “Savara Inc.” call.

Page:

Today's and Upcoming Events

  • Nov
    09

    SVRA to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    06

    SVRA announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.